| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced t... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced sec... |
| 22 Jul 2026 |
8-K: Regulation FD Disclosure
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, t... |
| 30 Jun 2026 |
8-K: Regulation FD Disclosure
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, t... |
| 26 Jun 2026 |
8-K: Regulation FD Disclosure
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 22, 2026, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,698,778 shares of the Company’s common stock were entitled to vote as of April 27, 2026, the record date for the Annual Meetin... |
| 29 May 2026 |
8-K: Regulation FD Disclosure
On May 29, 2026, Monopar Therapeutics Inc. (“Monopar”) presented results from a Phase 2 study (NCT04422431) evaluating the effect of ALXN1840 (tiomolibdate choline) on liver pathology and clinical symptoms in patients with Wilson disease... |
| 19 May 2026 |
8-K: Regulation FD Disclosure
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Wilmette, IL, May 14, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first ... |
| 20 Apr 2026 |
8-K: Regulation FD Disclosure
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition
Wilmette, Ill., March 27, 2026 – Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announce... |
| 02 Mar 2026 |
8-K: Regulation FD Disclosure
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Wilmette, IL, November 13, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced t... |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 |
| 24 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Pre-Funded Warrants to Purchase up to 960,542 Shares of Common Stock |
| 15 Sep 2025 |
8-K: Regulation FD Disclosure
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Wilmette, IL, August 12, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today an... |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,115,214 shares of the Company’s common stock were entitled to vote as of April 25, 2025, the record date for the Annual Meetin... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Wilmette, IL, May 13, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today annou... |
| 07 May 2025 |
8-K: Regulation FD Disclosure
WILMETTE, Ill, May 7, 2025 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long ter... |
Loading...